Pharma Capital

Clinigen unit and Diurnal Group team up to offer access to two drugs

Managed access programmes of the type overseen by Idis allow doctors to request unlicensed therapies for patients.
shutterstock_139652441.jpg
Access will be provided to two Diurnal treatments

Clinigen Group PLC’s (LON:CLIN) Idis Managed Access division has partnered with AIM drug developer Diurnal Group PLC (LON:DNL) to offer two Diurnal treatments.

Managed access programmes of the type overseen by Idis allow doctors to request unlicensed therapies for patients.

It’s often used as a way of making treatments available to people who have run out of options or were unable to take part in the clinical studies, but who may benefit from access to the treatment.

People will gain access in Europe Diurnal’s Infacort for paediatric patients with adrenal insufficiency and Chronocort to treat patients with congenital adrenal hyperplasia.

"The effective treatment of patients with CAH and paediatric AI represents a significant unmet need,” said Steve Glass, Clinigen’s chief commercial officer in North America and Europe.

“As the global leader in providing managed access programmes, we can leverage our international reach to support these patients by enabling their physicians to access these therapies safely, ethically and quickly, ahead of approval and launch."

Ian_55ae0ddd437b7.jpg
Why Invest In Clinigen Group PLC? Read More Here

Register here to be notified of future CLIN Company articles
View full CLIN profile

Clinigen Group PLC Timeline

View All

Related Articles

© biotech Capital 2017

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.